FibroBiologics, Inc. (FBLG)
Nasdaq · Healthcare · Biotechnology
$1.18−4.84%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $8.2M
- 52-week range
- $0.62 – $11.40
- 52-week change
- −88.73%
- EPS (trailing)
- −$5.01
Fiscal year to Dec 2025
- Net income
- −$18.6M
- Diluted EPS
- −$0.42
- Free cash flow
- −$16.7M
From the company’s annual report on SEC EDGAR.
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Headquarters: Houston, United States · 15 employees · fibrobiologics.com